TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27110711

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 4071
Study: 25701620

Group type: EXPERIMENTAL
Intervention: NIRS monitoring (INVOS 5100)
Number of subjects: 43

Group type: COMPARATOR
Intervention: No NIRS monitoring
Number of subjects: 43
Study: 23700339

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei CRL 431
Number of subjects: 494

Group type: COMPARATOR
Intervention: Regular calcium content milk (RC group)
Number of subjects: 494

Group type: COMPARATOR
Intervention: Low-lactose milk with low calcium content (LC group)
Number of subjects: 494
Study: 20519346

Group type: EXPERIMENTAL
Intervention: 0.1 mg rhTSH followed by a thyroid dose of 50 Gy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo followed by 100 Gy
Number of subjects: 90
Study: 18580042

Group type: EXPERIMENTAL
Intervention: EA/BA (EmbryoAssyst and BlastAssyst containing a novel stable glutamine derivative and vitamins)
Number of subjects: 41

Group type: COMPARATOR
Intervention: BAS (BlastAssyst system containing L‐glutamine)
Number of subjects: 41
Study: 16651222

Group type: EXPERIMENTAL
Intervention: Group 2: Family physicians received a summary of clinical practice guidelines at approximately 2 weeks postinjury.
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Group 3: Family physicians and their patients received a summary of clinical practice guidelines at approximately 2 weeks postinjury.
Number of subjects: 428

Group type: COMPARATOR
Intervention: Control Group 1: Neither the patients nor their family physicians received any information concerning the guidelines.
Number of subjects: 428
Study: 12792335

Group type: EXPERIMENTAL
Intervention: Anterior stabilization and fusion
Number of subjects: 52

Group type: COMPARATOR
Intervention: Posterior stabilization and fusion
Number of subjects: 52
Study: 10998833

Group type: EXPERIMENTAL
Intervention: Methylcobalamin 0.5 mg orally three times a day for 6 months
Number of subjects: 152

Group type: COMPARATOR
Intervention: Conventional management (patient education, physical therapy, and medication)
Number of subjects: 152
Study: 8634725

Group type: EXPERIMENTAL
Intervention: Intonation training using the Intonation Meter
Number of subjects: 2

Group type: COMPARATOR
Intervention: Regular methods of intonation training
Number of subjects: 2
Study: 1467255

Group type: EXPERIMENTAL
Intervention: Repeated testing attempts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Teacher factor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interaction of teacher factor and testing attempts
Number of subjects: 0
Study: 30794051

Group type: EXPERIMENTAL
Intervention: WRSS1 (3x106 CFU)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: WRSS1
Number of subjects: 103
Study: 28597117

Group type: EXPERIMENTAL
Intervention: Dexamethasone for 3 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Diclofenac sodium for 3 days
Number of subjects: 30
Study: 25654976

Group type: EXPERIMENTAL
Intervention: Peganum harmala L oil, applied 4 drops 3 times a day for 4 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Olive oil (control), applied 4 drops 3 times a day for 4 weeks
Number of subjects: 54
Study: 24727261

Group type: EXPERIMENTAL
Intervention: Anti-vascular endothelial growth factor treatment
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: Pro re nata treatment
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: Baseline predictors for sporadic vision loss
Number of subjects: 1185
Study: 22385527

Group type: EXPERIMENTAL
Intervention: Low pressure pneumoperitoneum (8 mm Hg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard pressure pneumoperitoneum (14 mm Hg)
Number of subjects: 100
Study: 19576348

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SESs), n = 196
Number of subjects: 397

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PESs), n = 201
Number of subjects: 397

Group type: COMPARATOR
Intervention: Control group (PESs)
Number of subjects: 397
Study: 18777000

Group type: EXPERIMENTAL
Intervention: Adenosine stress cardiac magnetic resonance imaging (CMRI)
Number of subjects: 141
Study: 15932376

Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone propionate (INFP) 200 microg o.d.
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (IHFP) 250 microg b.i.d.
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Combination of INFP and IHFP
Number of subjects: 262

Group type: COMPARATOR
Intervention: Intranasal placebo
Number of subjects: 262

Group type: COMPARATOR
Intervention: Inhaled placebo
Number of subjects: 262
Study: 12870789

Group type: COMPARATOR
Intervention: Global Improvement Scale (GIS)
Number of subjects: 0
Study: 10484014

Group type: EXPERIMENTAL
Intervention: CIFN 9 microg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: CIFN 3 microg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 8739595

Group type: EXPERIMENTAL
Intervention: HPMPC (cidofovir) at 1 mg/kg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: HPMPC (cidofovir) at 3 mg/kg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: HPMPC (cidofovir) at 10 mg/kg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 1832916

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Josamycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 6308830

Group type: EXPERIMENTAL
Intervention: Sultopride
Number of subjects: 94

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 94
Study: 30362839

Group type: EXPERIMENTAL
Intervention: Ceritinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 0
Study: 28733214

Group type: EXPERIMENTAL
Intervention: Opportunistic screening with algorithm B (quantifying only TG-IgA in all patients) in G2 (no restrictions on test referrals)
Number of subjects: 3818

Group type: EXPERIMENTAL
Intervention: Opportunistic screening with algorithm B in G2
Number of subjects: 3818

Group type: COMPARATOR
Intervention: Algorithm B in G1
Number of subjects: 3818

Group type: EXPERIMENTAL
Intervention: Algorithm B in G2
Number of subjects: 3818
Study: 25738338

Group type: EXPERIMENTAL
Intervention: Mucograft (MG; a porcine‐derived purified collagen membrane)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 24197612

Group type: EXPERIMENTAL
Intervention: Active training toward positive stimuli (n = 20)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo training (n = 22)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Nondepressive control (n = 33)
Number of subjects: 75
Study: 23072617

Group type: EXPERIMENTAL
Intervention: Formula supplemented with a mixture of dairy lipids and plant oils
Number of subjects: 75

Group type: COMPARATOR
Intervention: Formula containing only plant oils
Number of subjects: 75

Group type: COMPARATOR
Intervention: Formula containing plant oils supplemented with arachidonic acid and docosahexaenoic acid
Number of subjects: 75

Group type: COMPARATOR
Intervention: Breast-fed infants (reference group)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: All formulas
Number of subjects: 75
Study: 19460106

Group type: EXPERIMENTAL
Intervention: 100 mmol L(‐1) butyrate
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 50 mmol L(‐1) butyrate
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 11
Study: 17712121

Group type: EXPERIMENTAL
Intervention: MK‐0557 1 mg/d plus sibutramine 10 mg/d
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: MK‐0557 1 mg/d plus orlistat 120 mg TID
Number of subjects: 497

Group type: COMPARATOR
Intervention: Sibutramine 10 mg/d
Number of subjects: 497

Group type: COMPARATOR
Intervention: Orlistat 120 mg TID
Number of subjects: 497

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 497

Group type: COMPARATOR
Intervention: Sibutramine alone
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: MK‐0557 + sibutramine
Number of subjects: 497

Group type: COMPARATOR
Intervention: Orlistat alone
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: MK‐0557 + orlistat
Number of subjects: 497
Study: 15117091

Group type: EXPERIMENTAL
Intervention: Lumiracoxib 400 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lumiracoxib 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11803996

Group type: EXPERIMENTAL
Intervention: Tetric Ceram bonded with Excite
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ariston pHc bonded with Ariston Liner
Number of subjects: 24

Group type: COMPARATOR
Intervention: Tetric Ceram bonded with Prime and Bond NT
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ariston pHc bonded with Excite
Number of subjects: 24
Study: 9543158

Group type: COMPARATOR
Intervention: 375 IU urinary FSH, s.c., as a single injection on Day(LH+14) (group A; n = 11)
Number of subjects: 23

Group type: COMPARATOR
Intervention: 75 IU daily from Day(LH+19) until Day(LH+23) (group B; n = 12)
Number of subjects: 23
Study: 8058879

Group type: EXPERIMENTAL
Intervention: Distributed testing condition
Number of subjects: 56
Study: 2973849

Group type: EXPERIMENTAL
Intervention: hANP infusion (2 pmol min‐1 kg‐1 for 3 h)
Number of subjects: 7
Study: 29128897

Group type: EXPERIMENTAL
Intervention: Home-based SOP training (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No-contact control group (n = 30)
Number of subjects: 60
Study: 28827270

Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy or meniscal repair followed by standard postsurgical care
Number of subjects: 140

Group type: COMPARATOR
Intervention: 12-week individualised, supervised neuromuscular and strengthening exercise programme and patient education
Number of subjects: 140
Study: 26021223

Group type: EXPERIMENTAL
Intervention: Immediate loading
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Early loading
Number of subjects: 105

Group type: COMPARATOR
Intervention: Conventional loading
Number of subjects: 105
Study: 24302090

Group type: EXPERIMENTAL
Intervention: 8-session, simulation-based communication skills intervention (N=232)
Number of subjects: 472

Group type: COMPARATOR
Intervention: Usual education (N=240)
Number of subjects: 472
Study: 20862469

Group type: EXPERIMENTAL
Intervention: Half-dose gadolinium contrast
Number of subjects: 29

Group type: COMPARATOR
Intervention: Full-dose gadolinium contrast
Number of subjects: 29
Study: 18442632

Group type: EXPERIMENTAL
Intervention: Calorie restriction mimetic therapy with metformin for 3 years
Number of subjects: 60
Study: 16570675

Group type: EXPERIMENTAL
Intervention: Miconazole nitrate 0.25% ointment
Number of subjects: 330

Group type: COMPARATOR
Intervention: Vehicle control (zinc oxide/petrolatum)
Number of subjects: 330
Study: 12624492

Group type: EXPERIMENTAL
Intervention: ATRA + IFN
Number of subjects: 20

Group type: COMPARATOR
Intervention: IFN alone
Number of subjects: 20
Study: 10030325

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 10985

Group type: COMPARATOR
Intervention: Conventional therapy (diuretics, beta‐blockers)
Number of subjects: 10985

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 10985
Study: 8767350

Group type: EXPERIMENTAL
Intervention: Isradipine (5 mg)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Isradipine monotherapy
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Combination therapy (Isradipine + metoprolol/enalapril)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 55
Study: 1879388

Group type: EXPERIMENTAL
Intervention: Social-influences-based drug prevention program (Midwestern Prevention Project)
Number of subjects: 5008
Study: 6314747

Group type: EXPERIMENTAL
Intervention: Naloxone (10 micrograms/kg bolus followed by 5 micrograms/kg/h infusion)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Physiological saline (control)
Number of subjects: 9
Study: 31914115

Group type: EXPERIMENTAL
Intervention: Healthgrades certification reporting accuracy
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Mean star rating
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Factors associated with 5-star ratings
Number of subjects: 500
Study: 30019634

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid 100 mg/day plus intensive blood pressure treatment (targeted systolic blood pressure < 120 mmHg, monitored with a home blood pressure measuring device)
Number of subjects: 776

Group type: COMPARATOR
Intervention: Care as usual (no acetylsalicylic acid, targeted office systolic blood pressure < 140 mmHg, no home blood pressure measuring device)
Number of subjects: 776
Study: 28490022

Group type: EXPERIMENTAL
Intervention: COPE (Concurrent Treatment with Prolonged Exposure)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: RPT (Relapse Prevention Therapy)
Number of subjects: 110

Group type: COMPARATOR
Intervention: AMCG (Active Monitoring Control Group)
Number of subjects: 110
Study: 26633244

Group type: EXPERIMENTAL
Intervention: Kopstoring course (online 8-week group course with supervision by trained psychologists or social workers)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Kopstoring course
Number of subjects: 13
Study: 24260180

Group type: COMPARATOR
Intervention: Control arm of PATRICIA study
Number of subjects: 4825
Study: 21131371

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) 125 mg i.v.
Number of subjects: 48
Study: 18223010

Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study: 17022853

Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg b.i.d. with Metformin 1000 mg b.i.d.
Number of subjects: 13

Group type: COMPARATOR
Intervention: Metformin 1000 mg b.i.d. with Sitagliptin placebo
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sitagliptin 50 mg b.i.d. with Metformin placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Concomitant administration of Sitagliptin and Metformin
Number of subjects: 13
Study: 14618553

Group type: EXPERIMENTAL
Intervention: Olanzapine (5 mg/d, flexibly dosed to 5-20 mg/d)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Haloperidol (5 mg/d, flexibly dosed to 5-20 mg/d)
Number of subjects: 117
Study: 10846376

Group type: EXPERIMENTAL
Intervention: Black defendant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: White defendant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Life without the possibility of parole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Death penalty
Number of subjects: 0
Study: 9589926

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy and aspirin (group I, n = 15)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Aspirin only (group II, n = 49)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group (group III, n = 63)
Number of subjects: 127
Study: 8227340

Group type: EXPERIMENTAL
Intervention: Insulin-like growth factor I (IGF-I) 10 micrograms/kg.h
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 8
Study: 3080892

Group type: EXPERIMENTAL
Intervention: Pergolide (50 micrograms followed by 100 micrograms on the second day)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Pergolide (25 micrograms followed by 50 micrograms)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Pergolide (25 and 50 micrograms)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 22

Group type: COMPARATOR
Intervention: Both Pergolide and Bromocriptine
Number of subjects: 22
Study: 31868008

Group type: EXPERIMENTAL
Intervention: Multimodal pain relief
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (conventional analgesic treatment)
Number of subjects: 81
Study: 28673512

Group type: EXPERIMENTAL
Intervention: Ready! Set? Let's Train! (RST)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Homework Assistance (HWA)
Number of subjects: 17
Study: 26874683

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT-Cognitive Only)
Number of subjects: 63
Study: 25385727

Group type: EXPERIMENTAL
Intervention: Amrubicin 40 mg/m² IV on days 1 to 3
Number of subjects: 637

Group type: COMPARATOR
Intervention: Topotecan 1.5 mg/m² IV on days 1 to 5
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Amrubicin
Number of subjects: 637

Group type: COMPARATOR
Intervention: Topotecan
Number of subjects: 637
Study: 23524911

Group type: EXPERIMENTAL
Intervention: Total protein intake (energy%)
Number of subjects: 1319
Study: 20578378

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment at Shenshu (BL 23), Qihaishu (BL 24), Dachangshu (BL 25), and Pishu (BL 20) for 2 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Basic neurology therapies (Control group)
Number of subjects: 21
Study: 17554753

Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study: 16891991

Group type: EXPERIMENTAL
Intervention: Pamidronate infusion therapy
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (untreated patients with Paget's disease)
Number of subjects: 11
Study: 14702670

Group type: EXPERIMENTAL
Intervention: Bacterial vaginosis (BV) diagnosed by Gram stain
Number of subjects: 179

Group type: COMPARATOR
Intervention: Normal microflora
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Pathological culture
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: C. trachomatis infection
Number of subjects: 179
Study: 10950398

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 9194

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 9194

Group type: EXPERIMENTAL
Intervention: Blinded study drug alone
Number of subjects: 9194

Group type: EXPERIMENTAL
Intervention: Blinded drug plus hydrochlorothiazide (HCTZ)
Number of subjects: 9194

Group type: EXPERIMENTAL
Intervention: Blinded drugs plus HCTZ and additional drugs
Number of subjects: 9194

Group type: EXPERIMENTAL
Intervention: US patients
Number of subjects: 9194

Group type: EXPERIMENTAL
Intervention: Previously untreated patients
Number of subjects: 9194

Group type: EXPERIMENTAL
Intervention: Diabetics
Number of subjects: 9194

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 9194
Study: 8978804

Group type: EXPERIMENTAL
Intervention: 5'-DFUR (1,200 mg/day) administered preoperatively for 7 to 14 days
Number of subjects: 60
Study: 1442991

Group type: EXPERIMENTAL
Intervention: Spontaneous placental delivery
Number of subjects: 62

Group type: COMPARATOR
Intervention: Manual placental delivery
Number of subjects: 62
Study: 3519193

Group type: EXPERIMENTAL
Intervention: Prophylactic endoscopic paravariceal injection sclerotherapy (group IB)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Conservative treatment (group IA)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Prophylactic endoscopic paravariceal injection sclerotherapy (group II)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Regular monitoring and re-injection (group II)
Number of subjects: 71
Study: 31988643

Group type: EXPERIMENTAL
Intervention: Extra-curricular activities on reproductive health (seminars)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group (no extra-curricular activities)
Number of subjects: 400
Study: 29723995

Group type: EXPERIMENTAL
Intervention: ILAV A (4.68 percent body weight)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ILAV B (4.05 percent body weight)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ILAV C (3.71 percent body weight)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal station wear
Number of subjects: 0
Study: 27550880

Group type: EXPERIMENTAL
Intervention: Active laser acupuncture
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo laser acupuncture
Number of subjects: 62
Study: 21534678

Group type: EXPERIMENTAL
Intervention: HAPA-based educational leaflet and action planning intervention
Number of subjects: 201

Group type: COMPARATOR
Intervention: Standard government information leaflet
Number of subjects: 201
Study: 15659494

Group type: EXPERIMENTAL
Intervention: DF (docetaxel 75 mg/m(2) day 1, fluorouracil 200 mg/m(2) days 1 through 21, every 3 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: ECF (epirubicin 50 mg/m(2) day 1, cisplatin 60 mg/m(2) day 1, fluorouracil 200 mg/m(2) days 1 through 21, every 3 weeks)
Number of subjects: 90
Study: 12196334

Group type: EXPERIMENTAL
Intervention: 90Sr/90Y beta-radiation
Number of subjects: 476

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 476
Study: 9669790

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 24
Study: 8308973

Group type: EXPERIMENTAL
Intervention: Transdermal clonidine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 70
Study: 3181098

Group type: EXPERIMENTAL
Intervention: Riboflavin (200 mg), retinol (15 mg), and zinc (50 mg) supplement
Number of subjects: 610

Group type: COMPARATOR
Intervention: Placebo (D-mannitol)
Number of subjects: 610
Study: 4369018

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Upright posture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recumbent and upright positions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pheochromocytoma
Number of subjects: 0
Study: 11773179

Group type: EXPERIMENTAL
Intervention: Ranpirnase (Onconase; Alfacell Corp, Bloomfield, NJ), single weekly intravenous dose
Number of subjects: 105
Study: 31257186

Group type: EXPERIMENTAL
Intervention: Maternal patella lead exposure
Number of subjects: 248
Study: 30195953

Group type: EXPERIMENTAL
Intervention: 3 weeks of immobilization in a simple sling
Number of subjects: 120

Group type: COMPARATOR
Intervention: 6 weeks of immobilization in a brace with a small abduction pillow
Number of subjects: 120
Study: 27438182

Group type: EXPERIMENTAL
Intervention: Aripiprazole addition (adding aripiprazole to previous antipsychotics)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Aripiprazole switching (switching previous antipsychotics to aripiprazole)
Number of subjects: 52